An estimated 700,000 people worldwide live with MG.”
Myasthenia gravis (MG) is a chronic, rare, autoantibody-driven disease that interrupts communication between the nerves and muscles, causing muscle weakness. An estimated 700,000 people worldwide live with MG. There is currently no cure for MG, and vulnerable MG populations, like pediatric patients, have limited therapeutic options.
About 85 percent of cases progress to generalized myasthenia gravis (gMG), a serious form of MG characterized by severe muscle weakness and difficulties in speech and swallowing.
An estimated 700,000 people worldwide live with MG. ”
J&J’s approach to generalized myasthenia gravis
Building on our legacy of innovation in neuroscience and immunology, we’re advancing treatment options that can deliver meaningful clinical outcomes for people living with gMG. Our commercial portfolio includes an FDA-approved treatment for gMG in adults and pediatric patients.
We’re continuing to investigate this immunoselective treatment across multiple auto- and alloantibody-driven diseases, aiming to potentially address the underlying cause of disease without impacting other immune functions.
